318 related articles for article (PubMed ID: 17642399)
1. The beneficial effects of Xolair (omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV)--the Israeli arm of the INNOVATE study.
Sthoeger ZM; Eliraz A; Asher I; Berkman N; Elbirt D
Isr Med Assoc J; 2007 Jun; 9(6):472-5. PubMed ID: 17642399
[TBL] [Abstract][Full Text] [Related]
2. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.
Ohta K; Miyamoto T; Amagasaki T; Yamamoto M;
Respirology; 2009 Nov; 14(8):1156-65. PubMed ID: 19909462
[TBL] [Abstract][Full Text] [Related]
5. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
7. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
Bousquet J; Cabrera P; Berkman N; Buhl R; Holgate S; Wenzel S; Fox H; Hedgecock S; Blogg M; Cioppa GD
Allergy; 2005 Mar; 60(3):302-8. PubMed ID: 15679714
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
[TBL] [Abstract][Full Text] [Related]
9. Anti-IgE in severe persistent allergic asthma.
Fox H
Respirology; 2007 Nov; 12 Suppl 3():S22-8; discussion S45-7. PubMed ID: 17956516
[TBL] [Abstract][Full Text] [Related]
10. Adding long-acting beta-agonists to inhaled corticosteroids after discharge from the emergency department for acute asthma: a randomized controlled trial.
Rowe BH; Wong E; Blitz S; Diner B; Mackey D; Ross S; Senthilselvan A
Acad Emerg Med; 2007 Oct; 14(10):833-40. PubMed ID: 17898245
[TBL] [Abstract][Full Text] [Related]
11. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.
Flood-Page P; Swenson C; Faiferman I; Matthews J; Williams M; Brannick L; Robinson D; Wenzel S; Busse W; Hansel TT; Barnes NC;
Am J Respir Crit Care Med; 2007 Dec; 176(11):1062-71. PubMed ID: 17872493
[TBL] [Abstract][Full Text] [Related]
12. [Impact of preventive treatment with long-acting beta(2)-adrenergic agonists and inhaled corticosteroids on the morbidity and mortality of severe asthma exacerbations in 1543 patients].
Plaza V; Bellido-Casado J; Rodrigo GJ; Solarte I; Rodríguez-Trigo G; Sepúlveda R; Neffen H; Perpiñá M
Arch Bronconeumol; 2009 Nov; 45(11):545-9. PubMed ID: 19651467
[TBL] [Abstract][Full Text] [Related]
13. Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma.
Humbert M; Berger W; Rapatz G; Turk F
Allergy; 2008 May; 63(5):592-6. PubMed ID: 18355388
[TBL] [Abstract][Full Text] [Related]
14. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
Busse WW; Massanari M; Kianifard F; Geba GP
Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
[TBL] [Abstract][Full Text] [Related]
15. Improvement in quality of life with omalizumab in patients with severe allergic asthma.
Chipps B; Buhl R; Beeh KM; Fox H; Thomas K; Reisner C
Curr Med Res Opin; 2006 Nov; 22(11):2201-8. PubMed ID: 17076981
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.
Korn S; Thielen A; Seyfried S; Taube C; Kornmann O; Buhl R
Respir Med; 2009 Nov; 103(11):1725-31. PubMed ID: 19515548
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab as add-on therapy to inhaled steroids for asthma.
Hadj Tahar A
Issues Emerg Health Technol; 2004 Jun; (58):1-4. PubMed ID: 15455487
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.
Hanania NA; Alpan O; Hamilos DL; Condemi JJ; Reyes-Rivera I; Zhu J; Rosen KE; Eisner MD; Wong DA; Busse W
Ann Intern Med; 2011 May; 154(9):573-82. PubMed ID: 21536936
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
Sullivan SD; Turk F
Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
[TBL] [Abstract][Full Text] [Related]
20. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment.
Peters SP; Ferguson G; Deniz Y; Reisner C
Respir Med; 2006 Jul; 100(7):1139-51. PubMed ID: 16713224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
